Tumor-targeting engineered probiotic Escherichia coli Nissle 1917 inhibits colorectal tumorigenesis and modulates gut microbiota homeostasis in mice

Tang, Hao; Zhou, Tuoyu; Jin, Wei‐Lin; Zong, Simin; Mamtimin, Tursunay; Salama, E.; Jeon, Byong‐Hun; Liu, Pu; Han, Huawen; Li, Xiangkai

doi:10.1016/j.lfs.2023.121709

Cited by 9 publications

(7 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Synthetic probiotics have been engineered to significantly reduce CRC tumor size and inhibit tumor growth. These synthetic probiotics have also been shown to modulate the intestinal microbiota and attenuate chemically induced dysbiosis (185). Tang et al also demonstrated the inhibition of CRC and modulation of mice intestinal microbial homeostasis, providing further support for this approach (186).…”

Section: Engineered Bacteriamentioning

confidence: 98%

The role of the gut microbiota in tumor, immunity, and immunotherapy

Xie,

Liu

2024

Front. Immunol.

View full text Add to dashboard Cite

In recent years, with the deepening understanding of the gut microbiota, it has been recognized to play a significant role in the development and progression of diseases. Particularly in gastrointestinal tumors, the gut microbiota influences tumor growth by dysbiosis, release of bacterial toxins, and modulation of host signaling pathways and immune status. Immune checkpoint inhibitors (ICIs) have greatly improved cancer treatment efficacy by enhancing immune cell responses. Current clinical and preclinical studies have demonstrated that the gut microbiota and its metabolites can enhance the effectiveness of immunotherapy. Furthermore, certain gut microbiota can serve as biomarkers for predicting immunotherapy responses. Interventions targeting the gut microbiota for the treatment of gastrointestinal diseases, especially colorectal cancer (CRC), include fecal microbiota transplantation, probiotics, prebiotics, engineered bacteria, and dietary interventions. These approaches not only improve the efficacy of ICIs but also hold promise for enhancing immunotherapy outcomes. In this review, we primarily discuss the role of the gut microbiota and its metabolites in tumors, host immunity, and immunotherapy.

show abstract

Section: Engineered Bacteriamentioning

confidence: 98%

The role of the gut microbiota in tumor, immunity, and immunotherapy

Xie,

Liu

2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Dysbiosis of the intestine induces the secretion of proinflammatory cytokines and nitric oxide, which results in the occurrence of inflammation and CRC. Probiotics contribute to the reconstruction of the intestinal ecological balance and regulate the secretion of cytokines to restore intestinal homeostasis [22,25]. For example, a synbiotic combination of the probiotic Lactobacillus gasseri 505 and a prebiotic Cudrania tricuspidata leaf extract exerted a cancer-protective effect by downregulating pro-inflammatory cytokines in an azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced CRC mouse model [34].…”

Section: Mucosal Immunomodulationmentioning

confidence: 99%

“…Thus, in contrast to other reviews, we seek to fill this gap and carefully summarize the recent reports on bacteria and the bacterial delivery of therapeutic payloads for the treatment of CRC. This is followed by a discussion of different strategies to improve bacterial tumor-targeting ability [22,25]. The ultimate goal is to provide a reference for the development of more efficient and safer genetically engineered bacteria for CRC treatment in clinics.…”

Section: Introductionmentioning

confidence: 99%

A Review of the Use of Native and Engineered Probiotics for Colorectal Cancer Therapy

Han,

Zhang,

Tang

et al. 2024

IJMS

Self Cite

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a serious global health concern, and researchers have been investigating different strategies to prevent, treat, or support conventional therapies for CRC. This review article comprehensively covers CRC therapy involving wild-type bacteria, including probiotics and oncolytic bacteria as well as genetically modified bacteria. Given the close relationship between CRC and the gut microbiota, it is crucial to compile and present a comprehensive overview of bacterial therapies used in the context of colorectal cancer. It is evident that the use of native and engineered probiotics for colorectal cancer therapy necessitates research focused on enhancing the therapeutic properties of probiotic strains.. Genetically engineered probiotics might be designed to produce particular molecules or to target cancer cells more effectively and cure CRC patients.

show abstract

“…Previous studies have shown that probiotic bacteria from fermented food are effective in reducing the accumulation of excessive metabolites and harmful substances and in restoring the GM, thereby lowering the health risks associated with these substances. [10][11][12] Various approaches, such as fecal microbiota transplantation (FMT), probiotic mixtures, and prebiotics, have been explored for making general modifications to the microbiota in the treatment of IBD. However, with the rapid increase in the number of IBD patients, finding effective treatments remains a challenge.…”

Section: Introductionmentioning

confidence: 99%

A Probiotic Targets Bile Acids Metabolism to Alleviate Ulcerative Colitis by Reducing Conjugated Bile Acids

Jingjing,

Weilin,

Shaochen

et al. 2024

Molecular Nutrition Food Res

View full text Add to dashboard Cite

Scope: Gut microbiota (GM) dysbiosis and dysregulated bile acids (BAs) metabolism have been linked to ulcerative colitis (UC) pathogenesis. The possibility of utilizing live probiotics with a defined BAs‐metabolizing capability to modify the composition BAs for UC treatment remains unexplored.Methods and resultsIn this study, Strain GR‐4 is sourced from traditional Chinese fermented food, “Jiangshui,” and demonstrated the ability to deconjugate two common conjugated BAs by over 69% and 98.47%, respectively. It administers strain GR‐4 to dextran sulfate sodium (DSS)‐induced UC mice, and observes an overall alleviation of UC symptoms, as evidence by improved colon morphology, reduces inflammation and oxidative stress, and restores intestinal barrier function. Importantly, these effects are reliant on an intact commensal microbiota, as depletion of GM mitigated GR‐4s efficacy. Metabolomics analysis unveils a decline in conjugated BAs and an increase in secondary BAs following GR‐4 administration. GM analysis indicates that GR‐4 selectively enriches bacterial taxa linked to BAs metabolism, enhancing GM's capacity to modify BAs.ConclusionThis research demonstrates the potential for natural fermented foods and probiotics to effectively manipulate BAs composition, including conjugated and secondary BAs, to alleviate UC symptoms, underscoring the benefits of these approaches for gut health.

show abstract

Tumor-targeting engineered probiotic Escherichia coli Nissle 1917 inhibits colorectal tumorigenesis and modulates gut microbiota homeostasis in mice

Cited by 9 publications

References 74 publications

The role of the gut microbiota in tumor, immunity, and immunotherapy

The role of the gut microbiota in tumor, immunity, and immunotherapy

A Review of the Use of Native and Engineered Probiotics for Colorectal Cancer Therapy

A Probiotic Targets Bile Acids Metabolism to Alleviate Ulcerative Colitis by Reducing Conjugated Bile Acids

Contact Info

Product

Resources

About